Transcription-modulating drugs: Mechanism and selectivity

Current Opinion in Biotechnology

Volumn 7, Issue 6, 1996, Pages 608-615

  Cai, Weizhong ^a   Hu, Lan ^a   Foulkes, J Gordon ^a  

^a Oncogene Science Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CALCINEURIN; CYCLOSPORIN A; ESTROGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; SALICYLIC ACID DERIVATIVE; SOMATOMEDIN C; TACROLIMUS; TAMOXIFEN; THIAZOLIDINE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA3;

DRUG BINDING; DRUG MECHANISM; DRUG SELECTIVITY; GENETIC TRANSCRIPTION; INSULIN RESISTANCE; PRIORITY JOURNAL; REVIEW;

EID: 0030560814     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(96)80071-1     Document Type: Article

References (86)

1. Mitchell PJ, Tjian R. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science. 245:1989;371-378.
2. Stemmer PM, Klee CB. Dual calcium ion regulation of calcineurin by calmodulin and calcineurin B. Biochemistry. 33:1994;6859-6866.
3. Shaw KT-Y, Ho AM, Raghavan A, Kim J, Jain J, Park J, Surendra S, Rao A, Hogan PG. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. of special interest Proc Natl Acad Sci USA. 92:1995;11205-11209 This paper shows that NFAT1 (NFATp) in activated T cells is rapidly dephosphorylated followed by its nuclear localization and that dephosphoylation increases the affinity of NFAT1 for its specific sites in DNA. The paper also shows that CsA prevents the dephosphorylation.
4. Luo C, Shaw KT-Y, Raghavan A, Aramburu J, Garcia-Cozar F, Ferrino BA, Hogan PG, Rao A. Interaction of calcineurin with a domain of the transcription factor NFAT, that controls nuclear import. Proc Natl Acad Sci USA. 93:1996;8907-8912.
5. Jain J, McCaffrey PG, Valge-Archer VE, Rao A. Nuclear factor of activated T cells contains Fos and Jun. Nature. 356:1992;801-804.
6. Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, Curren T, Rao A. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature. 365:1993;352-355.
7. Frantz B, Nordby EC, Bren G, Steffan N, Paya CV, Kincaid RL, Tocci MJ, O'Keefe SJ, O'Neill EA. Calcineurin acts in synergy with PMA to inactivate IkB/MAD3, an inhibitor of NF-κB. EMBO J. 13:1994;861-870.
8. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophillin-cyclosporin A and FKBP-FK506 complex. Cell. 66:1991;807-815.
9. Sewell TJ, Lam E, Martin MM, Leszyk J, Weidner J, Calaycay J, Griffin P, Williams H, Hung S, Cryan J, Sigal NH, Weiderrecht GJ. Inhibition of calcineurin by a novel FK-506-binding protein. J Biol Chem. 269:1994;21094-21102.
10. Bram RJ, Hung DT, Martin PK, Schreiber SL, Crabtree GR. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: role of calcineurin binding and cellular location. Mol Cell Biol. 13:1993;4760-4769.
11. Galat A. Peptidylproline cis-trans-isomerases: immunophilins. Eur J Biochem. 216:1993;689-707.
12. Kawamura A, Su MS-S. Interaction of FKBP12-FK506 with calcineurin A at the B subunit-binding domain. J Biol Chem. 270:1995;15463-15466.
13. Kissinger CR, Parge HE, Knighton DR, Lewis CT, Pelletier LA, Tempczyk A, Kalish V, Tucker KD, Showalter RE, Moomaw EW, et al. Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature. 378:1995;641-644.
14. Park J, Yaseen NR, Hogan PG, Rao A, Sharma S. Phosphorylation of the transcription factor NFATp inhibits its DNA binding activity in cyclosporin A-treated human B and T cells. J Biol Chem. 270:1995;20653-20659.
15. Tumlin JA, Someren JT, Swanson CE, Lea JP. Expression of calcineurin activity and alpha-subunit isoforms in specific segments of the rat nephron. of outstanding interest Am J Physiol. 269:1995;F558-F563 This paper demonstrates that expression of calcineurin varies in different segments of the nephron and that calcineurin at higher levels is resistant to CsA and FK506.
16. Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK506 and cyclosporin A. Ann NY Acad Sci. 696:1993;9-19.
17. Su Q, Weber L, Le Hir M, Zenke G, Ryffel B. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Renal Physiol Biochem. 18:1995;128-139.
18. Dumont FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin CS, Harrison R, Sewell T, Kindt VM, Beattie TR, Wyvratt M, Sigal NH. The immunosuppressive and toxic effect of FK506 are mechanistically related: pharmacology of a novel antagonist of FK506 and rapamycin. J Exp Med. 176:1992;751-760.
19. Morris SM Jr, Kepka-Lenhart D, McGill RL, Curthoys NP, Adler S. Specific disruption of renal function and gene transcription by cyclosporin A. J Biol Chem. 267:1992;13768-13771.
20. Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP, Admon A, Crabtree GR. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature. 369:1994;497-502.
21. Wang DZ, McCaffrey PG, Rao A. The cyclosporin-sensitive transcription factor NFATp is expressed in several classes of cells in the immune system. Ann NY Acad Sci. 766:1995;182-194.
22. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 369:1994;756-758.
23. Sabatini DM, Erdjument-bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 78:1994;35-43.
24. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature. 377:1995;441-446.
25. Chung C, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth- dependent activation and signaling by the 70 kd S6 protein kinase. Cell. 69:1992;1227-1236.
26. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature. 358:1992;70-73.
27. Han J-W, Pearson RB, Dennis PB, Thomas G. Rapamycin, wortmannin, and the methylxanthin SQ20006 inactivate p70s6k by inducing dephosphorylation of the same sites. J Biol Chem. 270:1995;21396-21403.
28. Pearson RB, Dennis PB, Han J-W, Williamson NA, Kozma SC, Wettenhall REH, Thomas G. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J. 21:1995;5279-5287.
29. Jefferies HBJ, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the polypyrimidine tract mRNA family. Proc Natl Acad Sci USA. 91:1994;4441-4445.
30. De Groot RP, Ballou LM, Sassone-Corsi P. Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell. 79:1994;81-91.
31. Feuerstein N, Huang D, Prystowsky MB. Rapamycin selectively blocks interleukin-2- induced proliferating cell nuclear antigen gene expression in T lymphocyte. of special interest J Biol Chem. 270:1995;9454-9458 This paper reports that rapamycin selectively inhibits IL-2-induced PCNA mRNA expression. This inhibition is potentially mediated through inhibition of the interaction of CREB/ATF transcription factors with CRE elements in the PCNA promoter.
32. Miyazaki T, Liu Z-J, Kawahara A, Minami Y, Yamada K, Tsujimoto Y, Barsoumian EL, Perlmutter RM, Taniguchi T. Three distinct IL-2 signaling pathways mediated by bcl-2, c- myc, and lck cooperate in hematopoietic cell proliferation. of special interest Cell. 81:1995;223-231 This paper demonstrated a new pathway of IL-2-induced gene expression, the expression of bcl-2, which was sensitive to rapamycin.
33. Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK. Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor α expression. Cell Growth Differ. 5:1994;1275-1282.
34. Saeki T, Cristiano A, Lynch MJ, Brattain M, Kim N, Normanno N, Kenney N, Ciardiello F, Salomon DS. Regulation by estrogen through the 5-flanking region of the transforming growth factor α gene. Mol Endocrinol. 12:1991;1955-1963.
35. Kenney NJ, Saeki T, Gottardis M, Kim N, Garcia-Marales P, Martin MB, Normanno N, Ciardiello F, Day A, Cutler ML, Salomon DS. Expression of transforming growth factor α antisense mRNA inhibits the estrogen-induced production of TGFa and estrogen-induced proliferation of estrogen-responsive human breast cancer cells. J Cell Physiol. 156:1993;497-514.
36. Kawamura I, Lacey E, Mizota T, Tsujimoto S, Nishigaki F, Manda T, Shimomura K. The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells. Anticancer Res. 14:1994;427-432.
37. Murphy LJ, Ghahary A. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev. 11:1990;443-453.
38. Kleinman D, Karas M, Danilenko M, Arbei A, Roberts CT Jr, LeRoith D, Levy J, Sharoni Y. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-1 induced tyrosine phosphorylation and reduction in IGF binding proteins. of outstanding interest Endocrinology. 137:1996;1089-1095 This paper describes the differential activities of tamoxifen in IGF-1-stimulated tyrosine phosphorylation in Ishidawa endometrial cancer cells and how this phosphorylation is reduced in the presence of estradiol in MCF-7 mammary cancer cells.
39. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin JS, Glasebrook AL, Termine JD. Estrogen and raloxifene stimulate transforming growth factor-β3 gene expression in rat bone: a potential mechanism for estrogen-or raloxifene-mediated bone maintenance. of outstanding interest Endocrinology. 137:1996;2075-2084 This paper reports that estrogen and raloxifene, as well as tamoxifen to a lesser extent, stimulate TGF-β3 gene expression through a non-ERE region in the promoter. The authors also provide evidence that TGF-β3 may be important for bone maintenance.
40. Mangelsdorf DJ, Trummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumber B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell. 83:1995;835-839.
41. Gronemeyer H. A transcription activation by estrogen and progesterone receptors. Annu Rev Genet. 25:1991;89-123.
42. Vom Baur E, Zechel C, Heery D, Heine MJS, Garnier JM, Vivat V, Le Douarin B, Gronemeyer H, Chambon P, Losson R. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. of special interest EMBO J. 15:1996;110-124 This paper provides the evidence that potential transcription cofactors mSUG1 and TIF1 may interact with the AF-2 domain of nuclear receptors such as ER and RARα through different mechanisms or interfaces.
43. Halachmi S, Marden E, Martin G, Mackay H, Abbondanza C, Brown M. Oestrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science. 264:1994;1455-1458.
44. Cavailles V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ, Parker MG. Nuclear factor R1P140 modulates transcriptional activation by the estrogen receptor. EMBO J. 14:1995;3741-3751.
45. Webb P, Lopes GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. of special interest Mol Endocrinol. 9:1995;443-456 This paper reports that tamoxifen can activate promoter-bearing AP-1 sites in an AP-1-dependent fashion.
46. Metzger D, Ali S, Bornert J-M, Chambon P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. of special interest J Biol Chem. 270:1995;9535-9542 This paper reports that within the AF-1 domain there are at least two subdomains that can synergize with AF-2 in animal cells and at least three subdomains that are active in yeast cells.
47. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol. 9:1995;659-669.
48. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA. 89:1992;4037-4041.
49. Fawell SE, White R, Houre S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by "pure" antiestrogen ICI 164,384 appears to be mediated by impaired dimerization. Proc Natl Acad Sci USA. 87:1990;6883-6887.
50. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Down-regulation of transforming growth factor-α by tamoxifen in human breast cancer. Cancer. 72:1993;131-136.
51. Hana V, Murphy LJ. Expression of insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line. Endocrinology. 135:1994;2511-2516.
52. Huynh HT, Pollak M. Insulin-like growth factor 1 gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res. 53:1993;5585-5588.
53. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 329:1993;1141-1146.
54. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet. 343:1994;1318-1321.
55. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 326:1992;852-856.
56. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology. 135:1994;2001-2005.
57. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU. Raloxifene (LY139481HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 93:1994;63-69.
58. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, Magee DE, Termine JD, Bryant HU. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sci. 761:1995;355-360.
59. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481)HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 11:1996;835-842.
60. Hofmann CA, Edwards CW III, Hillman RM, Cola JR. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinology. 130:1992;735-740.
61. Saudouk T, Reda D, Hofmann CA. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A. Endocrinology. 133:1993;352-359.
62. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ J Biol Chem. 270:1995;12953-12956.
63. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
64. 2 and the thiazolidinedione class of drugs bind to PPARγ and activate the transcription through PPRE elements. The antidiabetic activity of thiazolidinediones correlates with the transactivation and the binding affinity to PPARγ.
65. Teboul L, Gaillard D, Staccini L, Inadera H, Amri EZ, Grimaldi PA. Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. J Biol Chem. 270:1995;28183-28187.
66. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:1993;87-91.
67. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-α J Clin Invest. 94:1994;1543-1549.
68. Hotamisligil CS, Spiegelman BM. Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes. 43:1994;1271-1278.
69. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 95:1995;2409-2415.
70. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 268:1993;26055-26058.
71. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology. 134:1994;264-270.
72. Szalkowske D, White-Carrington S, Berger J, Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 136:1995;1474-1481.
73. Ohsumi J, Sakakibara S, Yamaguchi J, Miyadai K, Yoshioka S, Fujiwara T, Horikoshi H, Serizawa N. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology. 135:1994;2279-2282.
74. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 265:1994;956-959.
75. Weismann G. Aspirin. Sci Am. 264:1991;84-90.
76. Malamy J, Carr JP, Klessig DF, Raskin I. Salicylic acid: a likely endogenous signal in the resistance response of tobacco to viral infection. Science. 250:1990;1002-1004.
77. Jurivitch DA, Sistonen L, Kroes RA, Morimoto RI. Effect of sodium salicylate on the human heat shock response. Science. 255:1992;1243-1245.
78. Baeuerle PA, Henkel T. Funtion and activation of NF-κB in the immune system. Annu Rev Immunol. 12:1994;141-179.
79. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. Salicylates inhibit IκB-α phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. of special interest J Immunol. 156:1996;3961-3969 This study indicates that aspirin and salicylates inhibit the activation of NF-κB by preventing the phosphorylation and subsequent degradation of IκB.
80. Vane J. Towards a better aspirin. Nature. 367:1994;215-216.
81. Dinchuk J, Car BB, Forcht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Caerniak PM, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 378:1995;406-409.
82. Zyglewska T, Sandu R, Ohashi K, Loose-Mitchell DS, Sanduja SK, Wu KK. Inhibition of endothelial cell prostaglandin H synthase gene expression by Naproxen. Biochim Biophys Acta. 1131:1992;78-82.
83. Hudson N, Hawthorne AB, Cole AT, Jones PD, Hawkey CJ. Mechanisms of gastric and duodenal damage and protection. Hepatogastroenterology. 39:1992;31-36. (suppl 1).
84. Salazar-Villa RM, Zambrano-Villa S. Asthma induced by aspirin and arachidonic acid metabolites: role of leukotrienes. Rev Alerg Mex. 41:1994;51-57.
85. Ivey KJ. Gastrointestinal interference and bleeding with non-narcotic analgesics. Drugs. 32:1987;71-89. (suppl 4).
86. Semble EL, Wu WC. Anti-inflammatory drugs and gastric mucosal damage. Semin Arthritis Rheum. 16:1987;271-286.